Polycystic Ovary Syndrome and Endometrial Cancer

ABSTRACT

An association between polycystic ovary syndrome (PCOS) and endometrial carcinoma was first suggested in 1949. Since then, several studies have been published that appear to support this association, and it is common practice among gynecologists and physicians to prescribe hormonal treatment to reduce this perceived risk, although there is no consensus as to the subgroup of PCOS in whom this is required. The mechanism(s) underlying any association are also unclear, but it is again widely assumed that chronic anovulation, which results in continuous estrogen stimulation of the endometrium unopposed by progesterone, is a major factor. However, obesity, hyperinsulinemia, and hyperandrogenism, which are also features of PCOS, are risk factors for endometrial carcinoma, but it does not necessarily follow that the incidence or mortality from endometrial cancer is increased in women with the syndrome. Potential strategies to prevent endometrial cancer in PCOS women are discussed.

KEYWORDS

Polycystic ovary syndrome - polycystic ovaries - endometrial hyperplasia - endometrial carcinoma

REFERENCES

• 1 Speert H. Carcinoma of the endometrium in young women.  Surg Gynecol Obstet. 1949;  88 332-336
• 2 Hardiman P, Pillay O S, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma.  Lancet. 2003;  361 1810-1812
• 3 Velazquez E M, Mendoza S G, Hamer T, Sosa F, Glueck C J. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinaemia, insulin resistance, hyperandrogenaemia, and systolic blood pressure, whilst facilitating normal menses and pregnancy.  Metabolism. 1994;  43 647-654
• 4 The Rotterdam ESHRE/ASRM Group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).  Hum Reprod. 2004;  19 41-47
• 5 Jackson R L, Dockerty M B. The Stein-Leventhal syndrome: analysis of 43 cases with special reference to association with endometrial carcinoma.  Am J Obstet Gynecol. 1957;  73 161-173
• 6 Stein I F, Leventhal M L. Amenorrhea associated with bilateral polycystic ovaries.  Am J Obstet Gynecol. 1935;  29 181-189
• 7 Jemal A, Thomas A, Murray T, Thun M. American Cancer Society Cancer Statistics, 2002.  CA Cancer J Clin. 2002;  52 23-47
• 8 Coleman M P, Rachet B, Woods L M et al.. Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001.  Br J Cancer. 2004;  90 1367-1373
• 9 Bray F, dos Santos Silva I, Moller H, Weiderpass E. Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention.  Cancer Epidemiol Biomarkers Prev. 2005;  14 1132-1142
• 10 Ramzy I, Nisker J A. Histologic study of ovaries of young women with endometrial carcinoma.  Am J Clin Pathol. 1979;  71 253-256
• 11 Soliman P T, Oh J C, Schmeler K M. Risk factors for young premenopausal women with endometrial cancer.  Obstet Gynecol. 2005;  105 575-580
• 12 Dockerty M B, Lovelady B, Foust G T et al.. Carcinoma of corpus uteri in young women.  Am J Obstet Gynecol. 1951;  61 966-981
• 13 Coulam C B, Annegers J F, Kranz J S. Chronic anovulation syndrome and associated neoplasia.  Obstet Gynecol. 1983;  61 403-407
• 14 Escobedo L G, Lee N C, Peterson H B, Wingo P A. Infertility-associated endometrial cancer risk may be limited to specific subgroups in infertile women.  Obstet Gynecol. 1991;  77 124-128
• 15 Gallup D G, Stock R J. Adenocarcinoma of the endometrium in women 40 years of age or younger.  Obstet Gynecol. 1984;  64 417-420
• 16 Dahlgren E, Friberg L G, Johansson S. Endometrial carcinoma: ovarian dysfunction-a risk factor in young women.  Eur J Obstet Gynecol Reprod Biol. 1991;  41 143-150
• 17 Konishi I, Koshiyama M, Mandai M et al.. Increased expression of LH/hCG receptors in endometrial hyperplasia and carcinoma in anovulatory women.  Gynecol Oncol. 1997;  65(2) 273-280
• 18 Ho S P, Tan K T, Pang M W, Ho T H. Endometrial hyperplasia and the risk of endometrial carcinoma.  Singapore Med J. 1997;  38 11-15
• 19 Pierpoint T, McKeigue P, Isaacs A J et al.. Mortality of women with polycystic ovary syndrome at long term follow up.  J Clin Epidemiol. 1998;  51 581-586
• 20 Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study.  Hum Fertil. 2000;  3 101-105
• 21 Pillay O C, Wong Te Fong L F, Crow J C et al.. The association between polycystic ovaries and endometrial cancer.  Hum Reprod. 2006;  21(4) 924-929
• 22 Luque-Ramirez M, Alvarez-Blasco F, Mendieta-Azcona C, Botella-Carretero J I, Escobar-Morreale H F. Obesity is the major determinant of the abnormalities in blood pressure found in young women with the polycystic ovary syndrome.  J Clin Endocrinol Metab. 2007;  92 2141-2148
• 23 Cibula D, Cifkova R, Fanta M, Poledne R, Zivny J, Skikoba J. Increased of NIDDM, arterial hypertension and coronary artery disease in perimenopausal women with a history of PCOS.  Hum Reprod. 2000;  15 785-789
• 24 Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus.  Fertil Steril. 2002;  77 1095-1105
• 25 Friberg E, Orsini N, Mantzoros C S, Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis.  Diabetologia. 2007;  50 1365-1374
• 26 Friberg E, Mantzoros C S, Wolk A. Physical activity and risk of endometrial cancer: a population-based prospective cohort study.  Cancer Epidemiol Biomarkers Prev. 2006;  15 2136-2140
• 27 Glintborg D, Henriksen J E, Andersen M et al.. Prevalence of endocrine diseases and abnormal glucose tolerance tests in 340 Caucasian premenopausal women with hirsutism as the referral diagnosis.  Fertil Steril. 2004;  82 1570-1579
• 28 Chang S C, Lacey J V, Brinton L A et al.. Lifetime weight history and endometrial cancer risk by type of menopausal hormone use in the NIH-AARP diet and health study.  Cancer Epidemiol Biomarkers Prev. 2007;  16 723-730
• 29 Furberg A S, Thune I. Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort.  Int J Cancer. 2003;  104 669-676
• 30 Birdsall M A, Farquhar C M. Polycystic ovaries in pre and post-menopausal women.  Clin Endocrinol (Oxf). 1996;  44 269-276
• 31 Winters S J, Talbott E, Guzick D S, Zborowski J, McHugh K P. Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome.  Fertil Steril. 2000;  73 724-729
• 32 Lukanova A, Lundin E, Micheli A et al.. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women.  Int J Cancer. 2004;  108 425-432
• 33 Nagamani M, Hannigan E V, Dillard E A, Van Dinh T. Ovarian steroid secretion in postmenopausal women with and without endometrial cancer.  J Clin Endocrinol Metab. 1986;  62 508-512
• 34 Potischman N, Hoover R N, Brinton L A et al.. Case-control study of endogenous steroid hormones and endometrial cancer.  J Natl Cancer Inst. 1996;  88 1127-1135
• 35 Schemeler K, Soliman P T, Sun C C, Slomovitz B M, Gershenson D M, Lu K H. Endometrial cancer in young, normal-weight women.  Gynecol Oncol. 2005;  99 388-392
• 36 Jafari K, Javaheri G, Ruiz G. Endometrial adenocarcinoma and the Stein-Leventhal syndrome.  Obstet Gynecol. 1978;  51 97-100
• 37 Farhi D C, Nosanchuk J, Silverberg S G. Endometrial adenocarcinoma in women under 25 years of age.  Obstet Gynecol. 1986;  68 741-745
• 38 Nakanishi T, Ishikawa H, Suzuki Y, Inoue T, Nakamura S, Kuzuya K. Association between menopausal state and endometrial cancer.  Int J Gynecol Cancer. 2001;  11 483-487
• 39 Pillay O C, Te Fong L F, Crow J C et al.. The association between polycystic ovaries and endometrial cancer.  Hum Reprod. 2006;  21 924-929
• 40 Soslow R A, Shen P, Chung M H, Isacson C, Baergen R N. Cyclin D1 expression in high-grade endometrial carcinomas-association with histologic subtype.  Int J Gynecol Pathol. 2000;  19 329-334
• 41 Giangrande P H, McDonnell D P. The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene.  Rec Prog Horm Res. 1999;  54 291-313
• 42 Masafumi Koshiyama K I, Mandai M. Increased expression of LH/hCG receptors in endometrial hyperplasia and carcinoma in anovulatory women.  Gynecol Oncol. 1997;  65 273-280
• 43 Dabizzi S, Noci I, Borri P et al.. Luteinizing hormone increases human endometrial cancer cells invasiveness through activation of protein kinase A.  Cancer Res. 2003;  63 4281-4286
• 44 Baillargeon J-P, Carpentier A. Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity.  Fertil Steril. 2007;  88 886-893
• 45 Pasquali R, Gamberi A. Polycystic ovary syndrome: a multifaceted disease from adolescence to adult age.  Ann N Y Acad Sci. 2006;  1092 158-174
• 46 Nagamani M, Stuart C A. Specific binding and growth-promoting activity of insulin in endometrial cancer cells in culture.  Am J Obstet Gynecol. 1998;  179 6-12
• 47 Bershtein L M, Gamaiunova V B, Kvachevskaia I O. The nature of hyperinsulinaemia (insulin resistance) in endometrial carcinoma: of plasma levels of insulin and c-peptide.  Vopr Onkol. 2000;  46 191-195
• 48 Soliman P T, Wu D, Tortolero-Luna G et al.. Association between adiponectin, insulin resistance, and endometrial cancer.  Cancer. 2006;  106 2376-2381
• 49 Bik W, Baranowska-Bik A, Wolinska-Witort E. The relationship between metabolic status and levels of adiponectin and ghrelin in lean women with polycystic ovary syndrome.  Gynecol Endocrinol. 2007;  23 325-331
• 50 Tada A, Sasaki H, Nakamura J, Yoshihama M, Terashima Y. Aromatase activity and the effect of estradiol and testosterone on DNA synthesis in endometrial carcinoma cell lines.  J Steroid Biochem Mol Biol. 1993;  44 661-666
• 51 Apparao K B, Lovely L P, Gui Y. Elevated endometrial androgen receptor expression in women with polycystic ovarian syndrome.  Biol Reprod. 2002;  66 297-304
• 52 Pillay O C, Leonard A, Sharkey A, Catalano R, Hardiman P. Endometrial gene expression in women with PCOS.  Human Reprod. 2005;  20(Supp 1) 20
• 53 Chen Y, Wang Y, Li M. Expression of apoptosis regulatory protein bcl-2 and bax in endometrium of polycystic ovary syndrome.  Zhonghua Fu Chan Ke Za Zhi. 1999;  34 652-654
• 54 MacLaughlan S D, Palomino W A, Mo B et al.. Endometrial expression of Cyr61: a marker of estrogenic activity in normal and abnormal endometrium.  Obstet Gynecol. 2007;  110 146-154
• 55 Orio Jr F, Palomba S, Cascella T et al.. Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study.  J Clin Endocrinol Metab. 2005;  90 6072-6076
• 56 Palomba S, Russo T, Orio Jr F et al.. Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome.  Hum Reprod. 2006;  21 457-465
• 57 Costello M F, Shrestha B, Eden J, Johnson N P, Sjoblom P. Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review.  Hum Reprod. 2007;  22 1200-1209
• 58 Cameron S T, Critchley H OD, Thong K J et al.. Effects of daily low dose mifepristone on endometrial maturation and proliferation.  Hum Reprod. 1996;  11 2518-2526
• 59 Narvekar N, Cameron S, Critchley H OD, Lin S, Cheng L, Baird D T. Low-dose mifepristone inhibits endometrial proliferation and up-regulates androgen receptor.  J Clin Endocrinol Metab. 2004;  89 2491-2497
• 60 Di Spiezio Sardo A, Radhakrishnan S. Endometrial carcinoma on continuous combined HRT: case report and literature review.  Maturitas. 2004;  48 171-175